Loading stock data…
$0.92+0.01 (+1.01%)
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
Lineage Cell Therapeutics, Inc. in the Healthcare sector is trading at $0.91 with a market capitalization of $276M. Wall Street consensus targets $5.50 (6 analysts), implying a +506.5% move over the next 12 months. The stock is currently near its 52-week low of $0.88, remaining 33.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.07M↓ | $1.73M↓ | $6.61M↑ | $3.68M↑ | $2.77M |
| Gross Profit | $1.07M↓ | $1.73M↓ | $6.54M↑ | $3.68M↑ | $2.73M |
| Operating Income | -$8.92M↓ | -$7.59M↓ | -$6.55M↓ | -$3.79M↑ | -$4.94M |
| Net Income | $1.48M↑ | -$4.81M↓ | $851,000↑ | -$29.78M↑ | -$30.46M |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment e...